查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103456

抗焦慮藥物市場：全球市場預測，2026-2032年

Anxiolytics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗焦慮藥物市場將成長至 23.7 億美元，複合年成長率為 7.53%。

主要市場統計數據
基準年 2025 14.2億美元
預計年份：2026年 15.4億美元
預測年份 2032 23.7億美元
複合年成長率 (%) 7.53%

抗焦慮藥物是精神健康照護中的核心治療藥物類別，用於治療整體焦慮症、恐慌症、急性躁動、失眠相關焦慮、手術焦慮以及精神科、神經科、基層醫療和急診醫學等科室中的合併症。此類別包括苯二氮平類藥物、丁螺環酮、羥嗪和其他抗組織胺、用於治療與表現相關的焦慮症狀的BETA阻斷劑、某些具有抗焦慮作用的抗憂鬱症，以及新興的非苯二氮平類藥物。世界衛生組織（WHO）指出，焦慮症仍然是全球最常見的精神疾病之一，其臨床負擔因常與其他疾病（如憂鬱症、物質使用障礙、心血管疾病、慢性疼痛和睡眠障礙）合併而進一步加重。推動這一趨勢的因素包括：精神健康篩檢的增加、遠距精神科醫療服務的普及、日益成長的職場和學業壓力，以及人們越來越認知到焦慮是一種需要持續治療的慢性復發性疾病。另一方面，許多速效抗焦慮藥物有鎮靜、跌倒、認知障礙、耐受性、依賴性、戒斷症狀、濫用和藥物交互作用等風險，因此處方決策仍受到嚴格監管，需要謹慎的臨床考量。因此，競爭環境和政策環境正在向更安全的處方、整合行為醫學、基於藥物基因體學的指南、數位監測以及循證治療路徑轉變，以平衡快速緩解症狀和長期功能恢復。

抗焦慮藥物領域的變革性變化

抗焦慮藥物領域正經歷著從症狀抑製到個體化、循序漸進和基於指標的心理健康護理的轉變。臨床指引日益強調謹慎使用苯二氮平類藥物、在適當情況下進行短期治療、病患教育、減量策略以及非藥物療法（例如認知行為療法和數位療法）的支持。醫療保健系統也優先考慮透過基層醫療篩檢和協作護理模式進行早期診斷，這提高了可在專科診療機構之外安全管理的藥物的重要性。監管機構和公共衛生部門持續監測受管制物質的處方、濫用風險、標籤要求和藥物安全監測數據，尤其關注老年人、孕婦、呼吸系統疾病患者以及使用鴉片類藥物或酒精等弱勢群體。同時，以神經生物學為基礎的藥物研發領域也不斷創新，包括GABA能、麩胺酸、血清素能、內源性大麻素、神經類固醇和壓力軸路徑調節。這些變化促使製藥公司、醫療保健提供者和保險公司優先考慮差異化的安全特性、藥物依從性支持、真實世界數據、濫用預防考慮以及能夠同時緩解急性焦慮和預防長期復發的綜合護理模式。

人工智慧對抗焦慮藥物領域的累積影響

人工智慧在抗焦慮藥物的整個價值鏈中扮演著日益重要的角色，尤其是在藥物發現、患者分層、臨床決策支援、藥物安全監測和醫療服務等領域。在研發方面，人工智慧模型可以分析生物路徑、分子庫、受體結合模式和臨床資料集，從而識別新的抗焦慮靶點，並在臨床試驗前最佳化候選化合物的選擇。在臨床實踐中，機器學習工具正被用於支援風險分層，其方法是將症狀評分量表、病歷、用藥依從性、睡眠模式、合併症概況以及從穿戴式裝置和遠端監測平台獲取的數位生物標記相結合。雖然這些功能有助於臨床醫生識別治療效果不佳、不利事件、藥物濫用或戒斷併發症較高的患者，但人工監督仍然至關重要。人工智慧也透過檢測電子病歷、不利事件報告和真實世界電子健康記錄中的安全訊號，增強了藥物安全監測，尤其是在抗焦慮藥物與鴉片類藥物、鎮靜劑、酒精或其他中樞神經系統抑制劑相互作用的情況下。然而，負責任的實施需要透明的檢驗、減少偏見、保護隱私、提供可解釋的建議，並遵守有關醫療設備、資料保護和管制藥品的相關法規。人工智慧的累積影響可能在提高處方準確性、加速開發更安全的分子以及支持持續監測心理健康等領域最為顯著，而不是取代臨床醫生的判斷。

關於抗焦慮藥物的關鍵區域性見解

在亞太地區，抗焦慮藥物的需求主要受患者群體大規模、心理健康意識增強、都市區壓力日益增加以及精神科與基層醫療日益融合等因素驅動；然而，大都會圈社區在醫療服務獲取方面仍然存在顯著差異。儘管中國、印度、日本、韓國和澳洲的心理健康政策框架正在不斷完善，但社會歧視、專科醫生短缺以及醫療保險報銷不平衡等問題仍然影響著診斷和治療途徑。在北美，人們對焦慮症的認知度較高，遠端醫療廣泛應用，藥物安全監測體係也較為完善，對管製藥物處方的監測力度不斷加大，尤其是在苯二氮平類藥物處方與鴉片類藥物暴露或濫用風險重疊的情況下。在拉丁美洲，由於社會經濟壓力、公共衛生舉措的擴展以及精神科服務取得方面的差異，對焦慮症治療的需求正在不斷成長。巴西和墨西哥憑藉其龐大的人口規模和不斷發展的醫療基礎設施，在區域醫療服務取得方面繼續發揮核心作用。在歐洲，重點在於加強法律規範、循證處方、公共醫療保險體係以及減少長期苯二氮平類藥物依賴，各國指南也日益推薦心理治療和謹慎的藥物治療。在中東，人們對精神健康服務的關注度日益提高，尤其是在都市區和高所得的海灣國家，但文化偏見和人員短缺正在影響人們的就醫行為。非洲由於精神衛生人員短缺、藥物獲取障礙和診斷不足，面臨著巨大的未滿足需求，但隨著精神衛生納入基層醫療和社區衛生項目，以及全球精神衛生舉措的支持，非洲的政策關注度正在不斷提高。

關於抗焦慮藥物的關鍵群體特定見解

在東協，抗焦慮藥物的使用受到醫療體系成熟度差異、快速都市化、私人醫療機構擴張以及政策層面日益關注精神健康等因素的影響。各國正努力改善精神科醫療服務的可近性，同時消除社會歧視和經濟負擔。在海灣合作理事會（GCC）國家，精神健康正透過國家醫療改革計劃、引入數位醫療以及投資專科醫療來實現現代化，但處方行為仍然受到管製藥物監管、文化態度以及居住者需求的影響。在歐盟，抗焦慮藥物的使用受到嚴格監管，這得益於藥物安全監測系統、統一的藥物安全標準以及各國為擴大社區精神衛生保健服務、減少長期鎮靜劑不當使用而做出的努力。在金磚國家，儘管患者數量龐大，但獲得專科醫生和藥物的機會卻參差不齊。因此，可擴展的基層醫療精神衛生模式、學名藥的普及、數位化分流以及與當地情況相關的臨床證據尤其重要。儘管七國集團（G7）國家在診斷基礎設施、保險報銷體系、老年人安全監測以及臨床指南遵循方面普遍表現出優勢，但它們也面臨著青少年、勞動年齡人口和老年人焦慮症治療需求日益成長的問題。許多北約成員國與高所得國家共享醫療保健系統，但在軍事、退伍軍人和創傷相關護理領域，抗焦慮藥物的重要性尤其突出。在這些情況下，焦慮症常常與創傷後壓力症候群、睡眠障礙、憂鬱症和慢性疼痛並存，因此需要謹慎選擇藥物並接受多學科支持。

各國抗焦慮藥物使用情況的關鍵訊息

在美國，焦慮症、遠距精神病學、管制藥物監測以及合併用藥的風險在臨床上備受關注，其治療路徑受到基層醫療、行為醫學整合以及保險覆蓋範圍差異的影響。在加拿大，公共衛生方法、省級處方指南以及擴大線上心理健康服務的覆蓋範圍受到重視，但農村和偏遠地區的醫療保健差距仍然存在。在墨西哥，人們對心理健康的認知正在提高，但經濟負擔、專家集中度和公共部門能力影響著抗焦慮藥物的取得。在巴西，對心理健康保健和完善的公共衛生基礎設施有著巨大的需求，但需求主要受焦慮、憂鬱症、社會經濟壓力以及精神科服務區域差異的影響。在英國，實證指引得到應用，優先考慮心理治療，並對鎮靜劑處方採取謹慎態度，同時輔以國家心理健康服務路徑和藥物安全計畫。德國受益於健全的保險報銷系統和便捷的專科醫生資源，其重點在於遵循指南的治療和鎮靜劑的風險管理。法國擁有廣泛的醫療保健涵蓋範圍，並積極監管藥品，但精神藥物的長期使用仍然是政策關注的重點。俄羅斯的治療需求受到壓力相關疾病、地區醫療資源分配不均以及不斷變化的藥品法規的影響。義大利和西班牙的公共醫療體系面臨著巨大的精神健康需求、人口老化以及改善社區焦慮症治療的努力。中國正透過政策改革、投資醫院和引入數位醫療來提升精神健康服務能力，但社會歧視和地區服務差異仍然是重大挑戰。印度面臨著巨大的未滿足需求、精神科醫生密度低以及遠距遠端醫療普及等問題，因此，擴充性且價格合理的抗焦慮治療以及與基層醫療的整合至關重要。在日本，人口老化加劇了人們對鎮靜劑、跌倒和多重用藥等安全問題的擔憂。同時，韓國民眾對數位醫療的接受度很高，心理健康意識也不斷增強，對保密醫療管道的需求也十分旺盛。在澳大利亞，完善的指導方針框架、遠端醫療以及公共心理健康政策已經到位，其重點仍然是確保處方安全，並讓本地及偏遠社區都能獲得醫療服務。

為行業領導者提供的實用建議

產業領導者應優先考慮更安全、差異化的抗焦慮藥物，尤其是那些能夠降低成癮、認知障礙、呼吸抑制、隔天鎮靜和戒斷症狀等風險的藥物。產品開發策略應納入真實世界數據、病患報告結果、功能恢復指標以及針對老年人、青少年、女性健康、合併憂鬱症、物質濫用風險和多重用藥族群的次族群分析。銷售和醫療團隊應遵循實證臨床指南、藥品監管合規性、藥物安全監測義務和負責任的處方教育，而非以銷售量為導向的促銷活動。機構可以透過為臨床醫生提供減量治療、藥物依從性、藥物交互作用檢查、遠端醫療追蹤和基於測量結果的護理工具來提升價值。數位化助理、人工智慧驅動的監測和行為療法整合的設計應充分考慮隱私、臨床相關性和公平性取得。在新興市場和醫療服務取得不足的市場，領導者應投資於降低醫療服務價格、確保醫療供應穩定可靠、提升心理健康素養、加強基層醫療培訓以及開展符合當地文化習慣的病人參與。監管、醫學事務、安全、市場進入和數位醫療團隊之間的跨職能協作對於建立信任和展現焦慮症治療領域的負責任創新至關重要。

調查方法

本執行摘要基於系統的二手研究方法，參考了公開可查且檢驗的資訊來源，包括同行評審的臨床文獻、監管公告、藥物安全監測出版物、精神衛生政策文件、臨床實踐指南、公共衛生報告以及世界衛生組織資源。研究途徑調查方法強調對臨床、監管、流行病學和醫療保健系統證據進行三角檢驗，以識別抗焦慮藥物使用、安全考慮、處方行為、獲取障礙和創新趨勢的一致模式。透過醫療保健基礎設施、精神衛生政策成熟度、管制藥品監管、服務可近性、污名化、人口趨勢和數位醫療應用等因素，解讀區域、群體和國家層面的具體見解。本分析不涉及市場規模估算、市場佔有率計算、收入估算和預測，而是著重於與策略決策相關的實證定性見解。所有研究結果均經過時效性、可靠性和適用性評估，並優先考慮權威醫學指南、系統綜述、官方衛生數據和既定法律規範。

結論

抗焦慮藥物領域正從以藥物為中心的模式轉向更廣泛的心理健康生態系統轉變，該生態系統優先考慮安全性、準確性、可及性和患者的長期療效。雖然人們對焦慮症的認知不斷提高，以及醫療管道的拓展提升了治療的可見度，但對藥物依賴、鎮靜劑濫用、誤用和多重用藥的擔憂正在推動處方標準的重組。人工智慧、數位醫療、藥物安全監測和分析以及個人化治療路徑為改善治療方案的選擇和監測提供了重要機遇，但它們的實施需要臨床檢驗和倫理管理。區域差異依然顯著，高所得國家的醫療保健系統專注於最佳化和降低風險，而新興地區則優先考慮可近性、增加醫療保健人員、降低醫療成本和減少歧視。對於行業領導者而言，成功的關鍵在於負責任的創新、遵循指南、以患者為中心的循證實踐以及與醫療保健系統合作，從而在不損害安全性的前提下提供有效的焦慮症治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗焦慮藥物市場：依藥物類別分類

  • 阿扎吡酮型
  • 苯二氮平類藥物
    • 中等效果
    • 長效型
    • 短效
  • 選擇性血清素再回收抑制劑
    • escitalopram
    • 帕羅西汀
    • 舍曲林
  • 正腎上腺素再回收抑制劑
    • Duloxetine
    • 文拉法辛

第8章：抗焦慮藥物市場：依給藥途徑分類

  • 鼻內給藥
  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈
    • 皮下

第9章：抗焦慮藥物市場：以劑型分類

  • 膠囊
    • 硬明膠
    • 軟明膠
  • 注射藥物
  • 口服懸浮液
  • 藥片
    • 緩釋
    • 立即生效

第10章：抗焦慮藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：抗焦慮藥物市場：以最終用戶分類

  • 診所
  • 居家照護環境
  • 醫院

第12章：抗焦慮藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：抗焦慮藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：抗焦慮藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Accord Healthcare US
  • Alvogen
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Dellwich Healthcare LLP
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Hameln Pharma GmbH
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lifecare Neuro Products Limited
  • Neurocon Inc.
  • Noreva Biotech
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C9948A

The Anxiolytics Market is projected to grow by USD 2.37 billion at a CAGR of 7.53% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.42 billion
Estimated Year [2026] USD 1.54 billion
Forecast Year [2032] USD 2.37 billion
CAGR (%) 7.53%

Anxiolytics are a core therapeutic category in mental health care, used to manage generalized anxiety disorder, panic disorder, acute agitation, insomnia-related anxiety, procedural anxiety, and comorbid symptoms across psychiatry, neurology, primary care, and emergency settings. The category includes benzodiazepines, buspirone, hydroxyzine and other antihistamine-based options, beta-blockers used for performance-related anxiety symptoms, and selected antidepressants with anxiolytic effects, alongside emerging non-benzodiazepine approaches. According to the World Health Organization, anxiety disorders remain among the most common mental health conditions globally, and their clinical burden is amplified by frequent coexistence with depression, substance use disorders, cardiovascular disease, chronic pain, and sleep disorders. Demand is shaped by expanded mental health screening, broader telepsychiatry access, growing workplace and academic stress, and recognition of anxiety as a chronic, recurrent condition requiring sustained care. At the same time, prescribing decisions remain highly regulated and clinically nuanced because many fast-acting anxiolytics carry risks related to sedation, falls, cognitive impairment, tolerance, dependence, withdrawal, misuse, and drug interactions. The competitive and policy environment is therefore moving toward safer prescribing, integrated behavioral health, pharmacogenomic guidance, digital monitoring, and evidence-based treatment pathways that balance rapid symptom relief with long-term functional recovery.

Transformative Shifts in the Anxiolytics Landscape

The anxiolytics landscape is being reshaped by a shift from symptom suppression toward personalized, stepped, and measurement-based mental health care. Clinical guidelines increasingly emphasize careful benzodiazepine use, short treatment durations where appropriate, patient education, tapering strategies, and non-pharmacological support such as cognitive behavioral therapy and digital therapeutics. Health systems are also prioritizing earlier diagnosis through primary care screening and collaborative care models, increasing the importance of medications that can be safely managed outside specialist settings. Regulatory agencies and public health authorities continue to monitor controlled-substance prescribing, diversion risks, labeling requirements, and pharmacovigilance data, particularly for vulnerable populations such as older adults, pregnant individuals, patients with respiratory disease, and people using opioids or alcohol. Simultaneously, innovation is advancing in neurobiology-driven drug development, including modulation of GABAergic, glutamatergic, serotonergic, endocannabinoid, neurosteroid, and stress-axis pathways. These shifts are encouraging manufacturers, healthcare providers, and payers to prioritize differentiated safety profiles, adherence support, real-world evidence, abuse-deterrence considerations, and integrated care models that address both acute anxiety relief and long-term relapse prevention.

Cumulative Impact of Artificial Intelligence on Anxiolytics

Artificial intelligence is becoming increasingly relevant across the anxiolytics value chain, particularly in drug discovery, patient stratification, clinical decision support, pharmacovigilance, and care delivery. In research and development, AI-enabled models can analyze biological pathways, molecular libraries, receptor-binding patterns, and clinical datasets to identify novel anxiolytic targets and optimize candidate selection before clinical testing. In clinical practice, machine learning tools are being used to support risk stratification by combining symptom scales, medical history, medication use, sleep patterns, comorbidity profiles, and digital biomarkers from wearables or remote monitoring platforms. These capabilities can help clinicians identify patients at higher risk of non-response, adverse events, misuse, or withdrawal complications, although human oversight remains essential. AI also strengthens pharmacovigilance by detecting safety signals from electronic health records, adverse event reports, and real-world prescribing data, especially where anxiolytics interact with opioids, sedatives, alcohol, or other central nervous system depressants. However, responsible deployment requires transparent validation, bias mitigation, privacy safeguards, explainable recommendations, and compliance with medical device, data protection, and controlled-substance regulations. The cumulative impact of AI is likely to be strongest where it improves prescribing precision, accelerates safer molecule development, and supports continuous mental health monitoring without replacing clinician judgment.

Key Regional Insights for Anxiolytics

In Asia-Pacific, anxiolytics demand is influenced by large patient populations, rising mental health awareness, expanding urban stressors, and increasing integration of psychiatry into primary care, while access gaps remain pronounced between metropolitan centers and rural communities. China, India, Japan, South Korea, and Australia are strengthening mental health policy frameworks, yet stigma, specialist shortages, and uneven reimbursement continue to shape diagnosis and treatment pathways. North America is characterized by high anxiety disorder recognition, broad use of telehealth, advanced pharmacovigilance infrastructure, and heightened scrutiny of controlled-substance prescribing, particularly where benzodiazepines overlap with opioid exposure and substance use risks. Latin America shows growing need for anxiety treatment amid socioeconomic stress, expanding public health initiatives, and variable access to psychiatric services; Brazil and Mexico remain central to regional access patterns due to their population scale and evolving healthcare infrastructure. Europe is guided by strong regulatory oversight, evidence-based prescribing, public reimbursement systems, and emphasis on reducing long-term benzodiazepine dependence, with national guidelines increasingly supporting psychological therapies and cautious pharmacotherapy. The Middle East is seeing rising attention to mental health services, especially in urban and high-income Gulf settings, while cultural stigma and workforce constraints influence treatment-seeking behavior. Africa faces significant unmet need due to limited mental health workforce capacity, medicine access barriers, and underdiagnosis, but policy attention is improving through integration of mental health into primary care and community health programs supported by global mental health initiatives.

Key Group Insights for Anxiolytics

Across ASEAN, anxiolytics use is shaped by diverse health system maturity, rapid urbanization, expanding private healthcare, and growing policy attention to mental health, with countries working to improve psychiatric access while addressing stigma and affordability. The GCC is advancing mental health modernization through national health transformation programs, digital health adoption, and investment in specialist care, while prescribing practices remain influenced by controlled-medication regulation, cultural attitudes, and expatriate population needs. The European Union provides a highly regulated environment for anxiolytics, supported by pharmacovigilance systems, harmonized medicine safety standards, and national efforts to reduce inappropriate long-term sedative use while expanding community-based mental health care. BRICS economies combine substantial patient populations with uneven access to specialists and medicines, making scalable primary care mental health models, generic availability, digital triage, and locally relevant clinical evidence particularly important. G7 countries typically demonstrate stronger diagnostic infrastructure, reimbursement mechanisms, geriatric safety monitoring, and clinical guideline adherence, while also facing rising demand for anxiety care among adolescents, working-age adults, and older adults. NATO member countries, many of which overlap with high-income health systems, show strong relevance for anxiolytics in military, veteran, and trauma-related care contexts, where anxiety frequently coexists with post-traumatic stress, sleep disorders, depression, and chronic pain, requiring careful medication selection and multidisciplinary support.

Key Country Insights for Anxiolytics

The United States has substantial clinical attention on anxiety disorders, telepsychiatry, controlled-substance monitoring, and co-prescribing risks, with treatment pathways shaped by primary care, behavioral health integration, and insurance coverage variation. Canada emphasizes public health approaches, provincial prescribing guidance, and growing access to virtual mental health services, while rural and remote communities continue to face care gaps. Mexico is expanding mental health recognition, but affordability, specialist concentration, and public-sector capacity influence anxiolytic access. Brazil has a large mental health care need and established public health infrastructure, with demand affected by anxiety, depression, socioeconomic stress, and regional disparities in psychiatric services. The United Kingdom applies evidence-based guidance that favors psychological therapies and cautious sedative prescribing, supported by national mental health service pathways and medication safety programs. Germany benefits from strong reimbursement systems and specialist access, with emphasis on guideline-based care and risk management for sedative-hypnotic medicines. France maintains broad healthcare access and active medicine surveillance, while long-term psychotropic use remains a policy focus. Russia faces treatment demand shaped by stress-related disorders, regional access variation, and evolving pharmaceutical regulation. Italy and Spain combine public healthcare coverage with significant mental health demand, aging populations, and efforts to improve community-based anxiety care. China is expanding mental health capacity through policy reform, hospital investment, and digital health adoption, though stigma and regional service imbalance remain important. India faces high unmet need, limited psychiatrist density, and growing telemedicine adoption, making scalable, affordable anxiolytic treatment and primary care integration critical. Japan's aging population heightens safety concerns around sedation, falls, and polypharmacy, while South Korea combines high digital health readiness with increasing mental health awareness and strong demand for confidential care channels. Australia has strong guideline frameworks, telehealth utilization, and public mental health initiatives, with continued focus on safe prescribing and access for rural and remote communities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize safer and more differentiated anxiolytic profiles, especially therapies that reduce risks of dependence, cognitive impairment, respiratory depression, next-day sedation, and withdrawal burden. Product development strategies should incorporate real-world evidence, patient-reported outcomes, functional recovery measures, and subgroup analyses for older adults, adolescents, women's health, comorbid depression, substance use risk, and polypharmacy. Commercial and medical teams should align with evidence-based clinical guidelines, controlled-substance compliance, pharmacovigilance obligations, and responsible prescribing education rather than volume-driven promotion. Organizations can strengthen value by supporting clinician tools for tapering, adherence, drug-interaction checks, telehealth follow-up, and measurement-based care. Digital companions, AI-enabled monitoring, and behavioral therapy integration should be designed with privacy, clinical validation, and equitable access in mind. In emerging and underserved markets, leaders should invest in affordability, supply reliability, mental health literacy, primary care training, and culturally adapted patient engagement. Cross-functional collaboration among regulatory, medical affairs, safety, market access, and digital health teams will be essential to build trust and demonstrate responsible innovation in anxiety treatment.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in publicly available and verifiable sources, including peer-reviewed clinical literature, regulatory agency communications, pharmacovigilance publications, mental health policy documents, clinical practice guidelines, public health reports, and international health organization resources. The methodology emphasizes triangulation across clinical, regulatory, epidemiological, and health system evidence to identify consistent patterns in anxiolytics use, safety considerations, prescribing behavior, access barriers, and innovation trends. Regional, group, and country insights are interpreted through healthcare infrastructure, mental health policy maturity, controlled-substance regulation, service accessibility, stigma, demographic patterns, and digital health adoption. The analysis excludes market sizing, market share calculation, revenue estimation, and forecasting, focusing instead on evidence-backed qualitative intelligence relevant to strategic decision-making. All findings are assessed for recency, credibility, and applicability, with priority given to recognized medical guidelines, systematic reviews, official health data, and established regulatory frameworks.

Conclusion

The anxiolytics landscape is evolving from a medication-centered model toward a broader mental health ecosystem that prioritizes safety, precision, access, and long-term patient outcomes. Rising awareness of anxiety disorders and expanding care channels are increasing treatment visibility, while concerns around dependence, sedation, misuse, and polypharmacy are reshaping prescribing standards. Artificial intelligence, digital health, pharmacovigilance analytics, and personalized treatment pathways offer meaningful opportunities to improve therapy selection and monitoring, but their adoption must be clinically validated and ethically governed. Regional differences remain significant, with high-income systems focused on optimization and risk reduction, while emerging regions prioritize access, workforce expansion, affordability, and stigma reduction. For industry leaders, success will depend on responsible innovation, guideline alignment, patient-centered evidence, and collaboration with healthcare systems to deliver effective anxiety care without compromising safety.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anxiolytics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Azapirones
  • 7.3. Benzodiazepines
    • 7.3.1. Intermediate Acting
    • 7.3.2. Long Acting
    • 7.3.3. Short Acting
  • 7.4. Selective Serotonin Reuptake Inhibitors
    • 7.4.1. Escitalopram
    • 7.4.2. Paroxetine
    • 7.4.3. Sertraline
  • 7.5. Serotonin Norepinephrine Reuptake Inhibitors
    • 7.5.1. Duloxetine
    • 7.5.2. Venlafaxine

8. Anxiolytics Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intranasal
  • 8.3. Oral
  • 8.4. Parenteral
    • 8.4.1. Intramuscular
    • 8.4.2. Intravenous
    • 8.4.3. Subcutaneous

9. Anxiolytics Market, by Form

  • 9.1. Introduction
  • 9.2. Capsule
    • 9.2.1. Hard Gelatin
    • 9.2.2. Soft Gelatin
  • 9.3. Injection
  • 9.4. Oral Suspension
  • 9.5. Tablet
    • 9.5.1. Controlled Release
    • 9.5.2. Immediate Release

10. Anxiolytics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Anxiolytics Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals

12. Anxiolytics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Anxiolytics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anxiolytics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Accord Healthcare US
  • 16.3. Alvogen
  • 16.4. Amneal Pharmaceuticals LLC
  • 16.5. Apotex Inc.
  • 16.6. AstraZeneca PLC
  • 16.7. Bausch Health Companies Inc.
  • 16.8. Dellwich Healthcare LLP
  • 16.9. Eli Lilly and Company
  • 16.10. F. Hoffmann-La Roche Ltd.
  • 16.11. GlaxoSmithKline PLC
  • 16.12. H. Lundbeck A/S
  • 16.13. Hameln Pharma GmbH
  • 16.14. Hikma Pharmaceuticals PLC
  • 16.15. Johnson & Johnson Services, Inc.
  • 16.16. Lifecare Neuro Products Limited
  • 16.17. Neurocon Inc.
  • 16.18. Noreva Biotech
  • 16.19. Novartis AG
  • 16.20. Pfizer Inc.
  • 16.21. Sanofi S.A.
  • 16.22. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANXIOLYTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANXIOLYTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANXIOLYTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANXIOLYTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANXIOLYTICS MARKET SIZE, BY FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANXIOLYTICS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANXIOLYTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANXIOLYTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANXIOLYTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANXIOLYTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANXIOLYTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANXIOLYTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANXIOLYTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL ANXIOLYTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ANXIOLYTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AZAPIRONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AZAPIRONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AZAPIRONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENZODIAZEPINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BENZODIAZEPINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BENZODIAZEPINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTERMEDIATE ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTERMEDIATE ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTERMEDIATE ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LONG ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LONG ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LONG ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SHORT ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHORT ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SHORT ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ESCITALOPRAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ESCITALOPRAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ESCITALOPRAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PAROXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PAROXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PAROXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SERTRALINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SERTRALINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SERTRALINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DULOXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DULOXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DULOXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VENLAFAXINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VENLAFAXINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VENLAFAXINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRANASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRANASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRANASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HARD GELATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HARD GELATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HARD GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOFT GELATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOFT GELATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SOFT GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMEDIATE RELEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 233. G7 ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. G7 ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. NATO ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 245. NATO ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. NATO ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. CANADA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 285. MEXICO ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. MEXICO ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. BRAZIL ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED KINGDOM ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 318. GERMANY ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 319. GERMANY ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 320. GERMANY ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 321. GERMANY ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. GERMANY ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 330. FRANCE ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 331. FRANCE ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 332. FRANCE ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 333. FRANCE ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. FRANCE ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 335. RUSSIA ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. RUSSIA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 340. RUSSIA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 341. RUSSIA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 342. RUSSIA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 343. RUSSIA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 344. RUSSIA ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 345. RUSSIA ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 346. RUSSIA ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 347. ITALY ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. ITALY ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 349. ITALY ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 350. ITALY ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 351. ITALY ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 352. ITALY ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 353. ITALY ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 354. ITALY ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 355. ITALY ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 356. ITALY ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 357. ITALY ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 358. ITALY ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 359. SPAIN ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 360. SPAIN ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 361. SPAIN ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 362. SPAIN ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 363. SPAIN ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 364. SPAIN ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 365. SPAIN ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 366. SPAIN ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 367. SPAIN ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 368. SPAIN ANXIOLYTICS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 369. SPAIN ANXIOLYTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 370. SPAIN ANXIOLYTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 371. CHINA ANXIOLYTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 372. CHINA ANXIOLYTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 373. CHINA ANXIOLYTICS MARKET SIZE, BY BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 374. CHINA ANXIOLYTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 375. CHINA ANXIOLYTICS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 376. CHINA ANXIOLYTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 377. CHINA ANXIOLYTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 378. CHINA ANXIOLYTICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 379. CHINA ANXIOLYTICS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)

TAB